T 1125/22 (Eliglustat/GENZYME) of 18.02.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T112522.20250218
- Date of decision
- 18 February 2025
- Case number
- T 1125/22
- Petition for review of
- -
- Application number
- 16175117.7
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Eliglustat (GENZ 112638) as inhibitor of glucosylceramide synthase for use in a method of treating Fabry's or Gaucher's disease, the method comprising adjusting the individual therapeutical dose to the P-450 metabolism of the patient
- Applicant name
- Genzyme Corporation
- Opponent name
- Teva Pharmaceutical Industries Ltd.
Accord Healthcare Ltd
Hetero Labs Limited - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 83
- Keywords
- Sufficiency of disclosure - completeness of disclosure (no)
- Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.